Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMBIT: Cisplatin + Irinotecan in Biliary Tract Cancer
NCT01859728Phase 2Unknown
- Sponsor
- Hospital de Amor
- Start
- Jan 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in biliary tract cancer (BTC) (2 arms), sponsored by Hospital de Amor. Primary endpoint: Overall Response Rate up to 24 weeks. Status: unknown.
02
Drugs
irinotecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01859728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859728.